Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protecting p53 from degradation.

S Laín1

  • 1Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, Scotland, U.K. s.lain@dundee.ac.uk

Biochemical Society Transactions
|March 26, 2003
PubMed
Summary

Cancer cells often inactivate the p53 protein, a key tumor suppressor. This study explores non-damaging ways to activate p53, focusing on leptomycin B

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SIRT1 and SIRT2 inhibition impairs pediatric soft tissue sarcoma growth.

Cell death & disease·2014
Same author

Numerical simulation of non-Newtonian blood flow dynamics in human thoracic aorta.

Computer methods in biomechanics and biomedical engineering·2014
Same author

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy.

British journal of cancer·2013
Same author

Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression.

Cell death & disease·2013
Same author

p53 as a therapeutic target.

The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·2008
Same author

The accuracy of reporting of general anaesthesia for childbirth: a validation study.

Anaesthesia and intensive care·2008

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Inactivation of the p53 tumor suppressor protein is prevalent in approximately 50% of human cancers.
  • Impaired p53 function, common in various cancers including childhood tumors, can result from altered cellular factors or viral oncoproteins.
  • Current cancer therapies like radiotherapy and chemotherapy activate p53 but cause long-term DNA damage.

Purpose of the Study:

  • To investigate novel strategies for non-genotoxic p53 activation.
  • To understand mechanisms regulating p53 stability for improved cancer treatment.
  • To examine the effects of leptomycin B on Mdm2 degradation and p14ARF oligomerization.

Main Methods:

  • Utilized leptomycin B, a nuclear export inhibitor, to study p53 response activation.
  • Investigated Mdm2 degradation pathways.
  • Assessed the oligomerization of p14ARF in response to oxidative stress.

Main Results:

  • Leptomycin B effectively activates the p53 response.
  • Observed Mdm2 degradation influenced by leptomycin B.
  • Provided evidence for p14ARF oligomerization under oxidative stress conditions.

Conclusions:

  • Understanding p53 regulation is key to developing non-genotoxic cancer therapies.
  • Leptomycin B shows potential for activating p53 without DNA damage.
  • Oxidative stress induces p14ARF oligomerization, impacting Mdm2 inhibition.

Related Experiment Videos